Physiomics PLC Collaborative Services Agreement (4257X)

TIDMPYC

RNS Number : 4257X

Physiomics PLC

26 April 2023

26 April 2023

Physiomics plc

("Physiomics" or "the Company")

Collaborative Services Agreement

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, announces the signature of a Collaborative Services Agreement with ValiRx's wholly owned subsidiary Inaphaea BioLabs Limited.

The agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO(R)) providing in-vitro laboratory-based services and Physiomics' in-silico capabilities for advanced statistical analyses, machine learning techniques, data handling and visualisation, as well as biological modelling.

Under the agreement, service users of Inaphaea will be able to benefit from Physiomics capabilities in a single service contract with Inaphaea. Designed to offer a seamless integration of data generation and data interpretation, this collaborative method of working provides benefits to both companies as well as to the service users.

Dr Jim Millen, CEO at Physiomics commented "The Collaborative Service Agreement will expand the scope of our core consulting business to discovery stage projects and improve our access to clients focused on earlier stages of drug development, while at the same time supporting Inaphaea's own service offering. The synergy is clear and both the scientific and commercial ambitions of our two companies are well matched. We look forward to working closely with ValiRx through this initiative"

Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative Services Agreement is the first step towards converting Inaphaea into a true tCRO(R). The Physiomics modelling skills will enable our clients to interpret and build on the data generated within the Inaphaea facility. I am delighted to be able to offer this additional service module to our clients. This additional value-added service will be available to our first service users, with benefits expected to increase as more complex data generation technologies are added to our capabilities"

This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

[phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes for Editors

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 40 targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRDZGZDDKRGFZM

(END) Dow Jones Newswires

April 26, 2023 02:00 ET (06:00 GMT)